WASHINGTON — The Koch-backed group Americans for Prosperity is pouring hundreds of thousands of dollars into a renewed push for federal “right-to-try” legislation that aims to give terminally ill patients a new way to access experimental therapies.
The six-figure ad campaign will include both targeted digital ads and a new national television ad that pulls seemingly supportive sound bites from Senate Majority Leader Chuck Schumer (D-N.Y.) as well as longtime proponent Sen. Ron Johnson (R-Wis.) and President Trump. The latter will air on both broadcast and cable channels.
About the Author Reprints
No legitimate pharmaceutical company would make any developmental drug available under this program. Only quacks like Stanislaw Burzynski with his “antineoplastons” would benefit from this license to fleece the rubes. The only effect would be to transfer money from the rubes to the quacks.
Glad to hear it . The oppponents keep talking about the FDAs’ exp. access as if it’s some wonderful program . It’s not. It’s pathetically small and slow. Those of us who have tried to gain access have had to fight through red tape while dying. Check out my wifes’ story : ” Lorraines’ Story ” on the Goldwater Institute RTT website. She did not have time to deal with the FDA bureaucracy at that time, in 2010. She had only months to live. Fortunately she did get one of the few spots in an exp. access program in Va. It saved her life . As a group access run by the private co., she did not have to fill out the hours long FDA paperwork for individual access. Her RTT story was filmed in early 2014. She is Stage IV but cancer – free over 6 years now. The FDA should not delay for even one day a dying persons’ chance at life. I say give them a notification and if they want to step in , let them . And they will have to justify any delay .
Is there a liability waiver that holds the manufacturer harmless should there be a severe adverse reaction that would expedite unexpected death. It seems like it would be an additional opportunity to get some good clinical data to possibly expedite the FDA approval for general access. It gives desperate patients HOPE which has a positive effect on their moral and Outlook.